Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL113923 | 0.67 | — | — | |
| Bromide SCHEMBL27814579 | 0.67 | — | — | |
| Ammonia Solution, Strong SCHEMBL28878962 | 0.65 | — | — | |
| SCHEMBL3084000 | 0.65 | — | — | |
| SCHEMBL2963807 | 0.65 | — | — | |
| SCHEMBL2961814 | 0.63 | — | — | |
| SCHEMBL28998325 | 0.63 | — | — | |
| SCHEMBL2043951 | 0.63 | — | — | |
| SCHEMBL29241969 | 0.63 | — | — | |
| SCHEMBL10514000 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2076515-B1 | THIOPHENE PYRAZOLOPYRIMIDINE COMPOUNDS | LILLY CO ELI (US) | 2013-07-17 | — | — | EP | disclosed |
| CN-101516886-B | Thiophene pyrazolopyrimidine compounds | LILLY CO ELI | 2012-02-29 | — | — | CN | disclosed |
| US-8110580-B2 | Thiophene pyrazolopyrimidine compounds | ELI LILLY AND COMPANY (US) | 2012-02-07 | — | — | US | disclosed |
| CN-101142217-B | Imidazopyridazine compounds | LILLY CO ELI | 2010-12-08 | — | — | CN | disclosed |
| US-20100022560-A1 | THIOPHENE PYRAZOLOPYRIMIDINE COMPOUNDS | CHEN ZHAOGEN | 2010-01-28 | — | — | US | disclosed |
| US-7612067-B2 | Imidazopyridazine compounds | ELI LILLY AND COMPANY (US) | 2009-11-03 | — | — | US | disclosed |
| CN-101516886-A | Thiophene pyrazolopyrimidine compounds | LILLY CO ELI (US) | 2009-08-26 | — | — | CN | disclosed |
| EP-2076515-A1 | THIOPHENE PYRAZOLOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2009-07-08 | — | — | EP | disclosed |
| US-7528134-B2 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES INC. (US) | 2009-05-05 | — | — | US | disclosed |
| EP-1869049-B1 | IMIDAZOPYRIDAZINE COMPOUNDS | LILLY CO ELI (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2008036541-A1 | THIOPHENE PYRAZOLOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2008-03-27 | — | — | WO | disclosed |
| CN-101142217-A | Imidazopyridazine compounds | LILLY CO ELI (US) | 2008-03-12 | — | — | CN | disclosed |
| EP-1869049-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006102194-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2006-09-28 | — | — | WO | disclosed |
| CN-1826317-A | Tyrosine kinase inhibitors | MERCK & CO INC (US) | 2006-08-30 | — | — | CN | disclosed |
| US-20060009461-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | BHATIA PRAMILA A | 2006-01-12 | — | — | US | disclosed |
| EP-1509213-A2 | ACETAMIDES AND BENZAMIDES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | Abbott Laboratories (US) | 2005-03-02 | — | — | EP | disclosed |
| US-20040029887-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2004-02-12 | — | — | US | disclosed |
| US-20030229094-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2003-12-11 | — | — | US | disclosed |
| WO-2003099266-A2 | ACETAMIDES AND BENZAMIDES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | ABBOTT LABORATORIES (US) | 2003-12-04 | — | — | WO | disclosed |